UCI Health
Irvine, Calif., – UCI Health, the clinical enterprise of the University of California, Irvine, has opened the world’s first in-human embryonic stem cell-derived clinical trial for Huntington’s disease.
The phase 1b/2a trial will evaluate the safety of hNSC-01 neural stem cells derived from embryonic stem cells which are precisely delivered to the brain by a specialized neurological mapping and targeting stereotactic system and performed in an MRI suite.
The trial is the result of many years of basic and translational science carried out at UCI, and funding by the California Institute of Regenerative Medicine (CIRM), to the research team led by Leslie M. Thompson, Ph.D., Donald Bren Professor of psychiatry and human behavior, as well as neurobiology and behavior, at UC Irvine…